The discovery that a single IV infusion of low-dose (subanesthetic) ketamine exerts rapid antidepressant effects constitutes an expansion in our understanding of the neurobiology of depression and provides new avenues for drug development.
Glutamatergic models have led to greater understanding of the causes of social and occupational disability in schizophrenia, and thus have provided new targets for remediation and compensation strategies. Details here.
Here's a fascinating study of consumer attitudes towards doctors among patients receiving antidepressants. The conclusions help us understand what goes wrong in the doctor-patient relationship and suggest steps needed to fix it.
How can we get even better at customizing treatment for our patients and thereby achieve improved outcomes? How do we avoid becoming relegated to mere brokers of psychopharmacologic commodities? A few thoughts in this brief communication.
What happens when our patients get pregnant or plan to get pregnant? What if psychiatric illness manifests during pregnancy or the perinatal period? Dr Elizabeth Fitelson answers these questions and more in this video.
What do we know about the relative efficacy of current medication and therapy for OCD? This question answered and highlights of recent studies, future directions, and causes are summarized in this video.
In this podcast, B. Andrew Farah, MD looks at shortcomings of current therapy that make treatment-resistant depression so common, offers insights into the genetic underpinnings of TRD, and focuses on a new treatment paradigm.
Keys to the management of panic disorder include appropriate use of psychotropic medication and psychotherapy predicated on an understanding of the disorder's biopsychosocial underpinnings. Here, Stephen V. Sobel, MD, focuses on treatment options.